Patrick Brzokewicz

Arterial Remodelling Technologies SA develops bioresorbable peripheral and coronary polymer stents. Its products includes ART PBS scaffold, procedure and Clinical data. The company was founded by Antoine Lafont, Michel Vert and J. Frederick Cornhill in 2001 and is headquartered in Paris, France.

Dépôts Pétroliers de Fos SA owns and operates petroleum tank terminals. It offers reception, storage and shipping services. The company was founded in 1970 and is headquartered in Fos-sur-Mer, France.

Société Du Port De Plaisance De Beauli engages in recreational and leisure activities.

Société Anonyme de Gestion de Stocks de Sécurité maintains crude oil and refined products reserves. The company was founded in 1988 and is headquartered in Paris La Défense, France.

Société Européenne De Stockage is a private company based in Strasbourg, France. Société Européenne De Stockage provides warehousing and non-refrigerated storage services. The French company was founded in 1975 and the CEO is Didier Clot.

Société du Pipeline Méditerranée-Rhône operates an oil pipeline. The company was founded in 1968 and is headquartered in Paris, France.

Société des Transports Petroliers par Pipeline SA operates and constructs pipeline networks. It also offers engineering; inspection; quality and metering; audits; consulting and training services. The company was founded in 1950 and is headquartered in Paris, France.

Société du Pipeline Sud-Européen is a private company based in Neuilly-sur-Seine, France. The French company specializes in the transport of petroleum products by pipeline and storage. The company has 40 floating roof bins on an area of 200 hectares in Fos-sur-Mer. The CEO of the company is Fabien Poure.

Gene Signal is a research based biotechnology company specialized in the discovery, development, and commercialization of a new class of oligonucleotides, proteins and monoclonal antibodies to treat a range of conditions where angiogenesis plays a determinant role. The company's innovative therapies use precisely targeted angiogenic (inducing vascular growth) or angiostatic (inhibiting vascular growth) agents, derived from genes that are exclusively involved with the angiogenesis process . The firm's therapies aim to provide a more targeted alternative to existing solutions like Vascular Endothelial Growth Factors which impact other physiological phenomena in addition to angiogenesis. Gene Signal's targeted therapies represents a novel, next-generation approach to the management of angiogenesis based conditions and offer the potential to improve treatment options for concerned patients. Founded in 2000, Gene Signal has assembled an strong leadership team that includes scientific, medical, regulatory, and business professionals with successful track records in developing and bringing to market state of the art drugs. Gene Signal continues to develop its angiogenesis modulating technology and has built a significant intellectual property portfolio, as well as a robust clinical and preclinical pipeline.

Medtronic France SAS provides medical equipment and medical technology services. The company was founded by Earl Bakken and Palmer Hermundslie in 1949 and is headquartered in Boulogne-Billancourt, France.

BASF France manufactures and markets coating products. The company is headquartered in Levallois-Perret, France.

Astra Zeneca Holding France SAS operates as a holding firm with interest in pharmaceuticals. The company was founded in 1994 and is headquartered in Rueil-Malmaison, France.

Aterovax SA develops in vitro diagnostic products for the management and assessment of cardiovascular diseases. Its products include diagnostic blood tests for determining and measuring activity of the cardiovascular biomarkers secretory phospholipase A2 (sPLA2) and secretory phospholipase A2-IIA (sPLA2-IIA) which provide physicians clinical information about the presence of a destabilized atherosclerotic plaque. The company was founded by Alain Tedgui, Ziad Mallat, Philippe Gabriel Steg, Joelle Benessiano and Jean-Marie Freyssinet on June 29, 2006 and is headquartered in Paris, France.

Gene Signal International SA engages in the development of drugs to manage angiogenesis based conditions. It is a research based biotechnology company specialized in the discovery, development, and commercialization of a new class of oligonucleotides, proteins and monoclonal antibodies to treat a range of conditions where angiogenesis plays a determinant role. The company was founded by Eric Viaud, Salman Al-Mahmood, and Eric Thorin in 2000 and is headquartered in Lausanne, Switzerland.

Sté Maritime de Combustibles Liquides de Boulogne-sur-Mer SA extracts and sells natural gas products. The company is headquartered in Boulogne-sur-Mer, France.